Brad L. Schoenfeld

The life sciences and pharmaceutical industries are experiencing significant transformation, driven by digital advancements and scientific innovations. Emerging companies face the challenge of rapidly bringing new products to market, often relying on partnerships that necessitate the swift execution of numerous contracts. Managing this influx can overwhelm in-house legal teams, diverting…

KO client Whitecap Biosciences, which is developing two innovative therapies for potential use in glaucoma and geographic atrophy, was recently acquired by Bausch + Lomb, a leading global eye health company to strengthen its expanding clinical stage pipeline. “Glaucoma and geographic atrophy can cause severe vision loss, with many patients…

KO client Cloudbreak Pharma, an innovative clinical-stage ophthalmology biotechnology company, recently announced that it has entered into a licensing agreement with Santen, a specialized company dedicated to eye health, to develop, manufacture, and commercialize its topical pterygium treatment. Cloudbreak founder and CEO Jinsong Ni said: “We are excited to partner…

A Texas federal court has struck down the Federal Trade Commission’s (FTC) proposed nationwide ban on non-compete agreements, just weeks before it was set to go into effect on September 4. This decision maintains the status quo and allows employers across the country to enforce non-compete clauses in accordance with…

In an effort to promote competition, protect workers’ rights, and foster innovation and new business formation, the Federal Trade Commission recently announced a significant rule aiming to ban non-competes between almost all employers and employees nationwide. If this regulation withstands existing and forthcoming legal scrutiny, employers won’t be able to…

Congratulations to KO Law partner Brad Schoenfeld on being recognized as one of the “Top 25 Attorneys of Colorado” by Attorney Intel. Brad and the selected attorneys exemplify the depth of legal talent in Colorado and have specialized practices in a number of areas. Over the last 20 years at…

KO client Predicine, Inc., a leading molecular insights company committed to advancing precision medicine in oncology, recently announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PredicineCARE™ as a companion diagnostic assay in localized bladder cancer. The collaboration represents progress in using comprehensive genomic profiling…

KO pro bono client Elpida Therapeutics’ mission is to deliver gene therapies to patients with ultra-rare diseases that are non-commercially viable and overlooked by traditional biotech and pharmaceutical companies. By leveraging scientific advancements and gene therapies, Elpida aims to provide treatments for children and families that desperately and urgently need…